🚨 The daily OncoAlert Newsletter is LIVE from Madrid 🇪🇸 #ESMO26
REGISTER for Free 👉 https://buff.ly/N5gYtAc
DELIVER STRAIGHT TO YOUR INBOX EVERY MORNING
Day One #ESMO26 is in:
📌 NATALEE 6-yr OS
📌 PANKU-Breast01 + Lancet pub
📌 KEYNOTE-866 & ENERGIZE, both negative in MIBC
📌 HERIZON-GEA-01 3-yr OS
For colleagues… by colleagues 🤝
Subscribe 👉 http://OncoAlert360.com
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
2035 浏览 · 18 赞 · 12 转发 · 1 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- OncoAlert@OncoAlert
The listed trials are not the COMPLETE list of trials included. There are many more that will be there!
来源：OncoAlert · x.com